Advisory Research Inc. Lowers Position in Neurocrine Biosciences, Inc. (NBIX)

Advisory Research Inc. lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 52.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 7,167 shares of the company’s stock after selling 7,808 shares during the period. Advisory Research Inc.’s holdings in Neurocrine Biosciences were worth $556,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NBIX. The Manufacturers Life Insurance Company boosted its holdings in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares in the last quarter. Crow Point Partners LLC purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $145,000. M&T Bank Corp purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $202,000. Comerica Bank purchased a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $210,000. Finally, CIBC Asset Management Inc purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $230,000.

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $85.25 on Monday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 14.37 and a current ratio of 10.20. Neurocrine Biosciences, Inc. has a 12-month low of $39.21 and a 12-month high of $91.82. The stock has a market cap of $7,540.00, a P/E ratio of -52.30, a PEG ratio of 279.10 and a beta of 0.26.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.11). The company had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same period in the prior year, the company earned ($0.51) EPS. sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post -0.11 earnings per share for the current year.

In related news, CEO Kevin Charles Gorman sold 3,750 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $78.89, for a total transaction of $295,837.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $75.04, for a total value of $471,176.16. Following the transaction, the insider now owns 19,436 shares of the company’s stock, valued at $1,458,477.44. The disclosure for this sale can be found here. Insiders have sold a total of 337,950 shares of company stock valued at $26,613,876 over the last 90 days. Insiders own 4.80% of the company’s stock.

NBIX has been the subject of a number of research reports. Oppenheimer set a $100.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, February 14th. Needham & Company LLC lifted their price target on shares of Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Deutsche Bank lifted their price target on shares of Neurocrine Biosciences to $97.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Leerink Swann reiterated an “outperform” rating and set a $83.00 price target (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, BidaskClub upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Neurocrine Biosciences presently has a consensus rating of “Buy” and an average price target of $88.79.

TRADEMARK VIOLATION NOTICE: “Advisory Research Inc. Lowers Position in Neurocrine Biosciences, Inc. (NBIX)” was first published by Week Herald and is the property of of Week Herald. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://weekherald.com/2018/02/19/advisory-research-inc-lowers-position-in-neurocrine-biosciences-inc-nbix.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply